These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 998400)

  • 1. Age-dependent regression of M-MSV tumors in CBA/H mice: requirement for a macrophage-adherent cell population.
    Stutman O
    Adv Exp Med Biol; 1976; 73 Pt B():371-8. PubMed ID: 998400
    [No Abstract]   [Full Text] [Related]  

  • 2. T lymphocyte requirement for MSV tumour prevention or regression.
    Collavo D; Colombatti A; Chieco-Bianchi L
    Nature; 1974 May; 249(453):169-70. PubMed ID: 4545519
    [No Abstract]   [Full Text] [Related]  

  • 3. Delayed tumour appearance and absence of regression in nude mice infected with murine sarcoma virus.
    Stutman O
    Nature; 1975 Jan; 253(5487):142-4. PubMed ID: 1110765
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
    Wood GW
    Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection.
    Collavo D; Colombatti A; Biasi G; Chieco-Bianchi L; Davies AJ
    J Natl Cancer Inst; 1976 Mar; 56(3):603-8. PubMed ID: 176399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.
    Chieco-Bianchi L; Colombatti A; Collavo D; Sendo F; Aoki T; Fischinger PJ
    J Exp Med; 1974 Nov; 140(5):1162-79. PubMed ID: 4608945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic control of oncogenesis by murine sarcoma virus Moloney pseudotype. I. Genetics of resistance in AKR mice.
    Colombatti A; Collavo D; Biasi G; Chieco-Bianchi L
    Int J Cancer; 1975 Sep; 16(3):427-34. PubMed ID: 170219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.
    Kirchner H; Chused TM; Herberman RB; Holden HT; Lavrin DH
    J Exp Med; 1974 Jun; 139(6):1473-87. PubMed ID: 4598016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking effect of serum from tumor-bearing animals on macrophage migration inhibition with tumor antigens.
    Halliday WJ
    J Immunol; 1971 Mar; 106(3):855-7. PubMed ID: 5547301
    [No Abstract]   [Full Text] [Related]  

  • 11. Macrophage migration inhibition with mouse tumor antigens: properties of serum and peritoneal cells during tumor growth and after tumor loss.
    Halliday WJ
    Cell Immunol; 1972 Jan; 3(1):113-22. PubMed ID: 5061636
    [No Abstract]   [Full Text] [Related]  

  • 12. Progressing Moloney sarcoma virus (M-MSV) induced tumors: effect of host's immunomanipulation.
    Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
    Cell Mol Biol Incl Cyto Enzymol; 1980; 26(2):155-8. PubMed ID: 6970620
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction and regression of primary moloney sarcoma virus-induced tumors in mice.
    Fefer A; McCoy JL; Glynn JP
    Cancer Res; 1967 Sep; 27(9):1626-31. PubMed ID: 4860892
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: no requirement for exogenous C5.
    Fuson EW; Walia AS; Cox BA; Lamon EW
    Clin Immunol Immunopathol; 1979 Sep; 14(1):35-46. PubMed ID: 477041
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy of primary Moloney sarcoma-virus-induced tumors.
    Fefer A
    Int J Cancer; 1970 May; 5(3):327-37. PubMed ID: 5452066
    [No Abstract]   [Full Text] [Related]  

  • 16. Lymphoma development in AKR : CBA/H-T6Crc chimaeras derived by neonatal injection of spleen cells.
    Tuffrey M; Crewe P; Barnes RD
    Eur J Cancer (1965); 1979 Apr; 15(4):387-93. PubMed ID: 220053
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics of inflammation and sarcoma cell development in primary Moloney sarcoma-virus-induced tumors.
    Becker S; Haskill S
    Int J Cancer; 1981 Feb; 27(2):229-34. PubMed ID: 7287218
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice.
    Fefer A; McCoy JL; Perk K; Glynn JP
    Cancer Res; 1968 Aug; 28(8):1577-85. PubMed ID: 4876979
    [No Abstract]   [Full Text] [Related]  

  • 19. The cellular events associated with regression and progression of murine (Moloney) sarcomas.
    Russell SW; Cochrane CG
    Int J Cancer; 1974 Jan; 13(1):54-63. PubMed ID: 4856384
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on immunity to autochthonous mouse tumors.
    Hellström I; Hellström KE; Pierce GE; Fefer A
    Transplant Proc; 1969 Mar; 1(1):90-4. PubMed ID: 5406848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.